PRO-C8
A fragment of the NC1 domain of type VIII collagen, enabling non-invasive monitoring of epithelial basement membrane remodeling and tumor-associated fibrosis in solid tumors.
Key features and values
- Quantifies NC1 domain fragments of type VIII collagen associated with basement membrane remodeling.
- Reflects epithelial cell-mediated extracellular matrix dynamics.
- Provides a non-invasive measure of tumor-associated fibrosis in various solid tumors.
- Supports monitoring of disease progression and response to therapies targeting tumor stroma.
- Applicable in research on cancers characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix remodeling in cancer.
- Complements other biomarkers for a comprehensive assessment of tumor microenvironment dynamics.
Description
The PRO-C8 biomarker assay measures specific fragments of the NC1 domain of type VIII collagen, serving as an indicator of epithelial basement membrane remodeling and tumor-associated fibrosis in various solid tumors. This non-invasive assay provides insights into tissue remodeling processes associated with cancer progression. By quantifying type VIII collagen degradation products, the PRO-C8 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tumor stroma remodeling. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in oncology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
